Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net profit, reaching Rs 2,278 crore. Despite this dip, revenue from operations increased by 10% to Rs 13,786 crore. Strong performance in the India market and growth in global innovative medicines sales, including the U.S. launch of LEQSELVI, contributed to the company’s overall progress.
US inflation tops 4% for first time in three years, keeping Fed hike in play
US inflation climbed to 4.1% in May, driven by rising energy prices, keeping the Federal Reserve’s interest rate hike plans on the table for September.